Latest news for Roscan Gold (OTC:RCGCF) Stock

Roscan Gold Corp is a Canadian gold exploration company focused on the exploration and acquisition of gold properties in West Africa. The company has assembled a land position in an area of producing gold mines and gold deposits, located both north and south of its Kandiole Project in West Mali.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

ACHV

ACRX

AGEEF

AHPI

ALNA

ALTM

APDN

ARREF

ASRT

ATYG

AXLA

BCRX

BIDCF

BLILF

BLUE

BSRC

BTLLF

CASA

CCTR

CHKVP

CMCT

CTRA

CURN

CYCN

DIGAF

DOGZ

DRRSF

DYNT

EARS

ENCTF

ETSY

EXTN

FACO

FANG

FCUUF

FIXX

FLDM

FOSL

FTSI

GIFI

GLOG

GLOP

HMLP

HQGE

HUDRF

IDEX

IFMK

IMEXF

KERN

KNRLF

LGORF

LKSD

LPCN

LUCRF

MBIOF

MFCSF

MGNX

MGTI

MICCF

MITK

NBLX

NINE

NEXTSOURCE MATERIALS CDA by Nextsource Materials Inc.

NSRCF

OCGN

OLVRF

PAGP

PDMI

PEMIF

PETQ

PLATEAU URANIUM INC by Plateau Uranium Inc.

PLUUF

RBBN

RCGCF

RGBP

RIGH

RVLV

RVVTF

SCNNF

SDRL

SEEK

SITO

SMLP

STIM

STLHF

SWIR

SYHBF

SYRS

TBEV

TGGI

TIGO

TLCC

TOPS

TRPX

Stocks That Hit 52-Week Lows On Monday

Roscan Gold Corp

<p>Guggenheim  analyst Michael Morris   maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $44 to $45.</p>


Price Target

Analyst Ratings

FOXA

Guggenheim Maintains Buy on Fox, Raises Price Target to $45

<p><a href="https://www.youtube.com/watch?v=4jDyPMVkuh4" title="https://www.youtube.com/watch?v=4jDyPMVkuh4">https://www.youtube.com/watch?v=4jDyPMVkuh4</a></p>


Politics

Events

'LIVE: Trump delivers remarks on the tax code and inflation in Georgia' - Fox News

<p>Deep-pocketed investors have adopted a bearish approach towards Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ABNB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Airbnb. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 36% leaning bullish and 54% bearish. Among these notable options, 6 are puts, totaling $299,641, and 5 are calls, amounting to $229,365.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $160.0 for Airbnb, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Airbnb's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Airbnb's significant trades, within a strike price range of $60.0 to $160.0, over the past month.</p>
<h3>Airbnb Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197295_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$30.05</td>
<td>$28.85</td>
<td>$29.9</td>
<td>$160.00</td>
<td>$74.7K</td>
<td>1.5K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$73.95</td>
<td>$72.55</td>
<td>$73.01</td>
<td>$60.00</td>
<td>$73.0K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$3.95</td>
<td>$4.0</td>
<td>$100.00</td>
<td>$68.4K</td>
<td>2.8K</td>
<td style="text-align: right;">490</td>
</tr>
<tr>
<td>ABNB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$10.55</td>
<td>$10.5</td>
<td>$10.5</td>
<td>$130.00</td>
<td>$53.5K</td>
<td>1.3K</td>
<td style="text-align: right;">53</td>
</tr>
<tr>
<td>ABNB</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.0</td>
<td>$12.85</td>
<td>$13.0</td>
<td>$125.00</td>
<td>$50.7K</td>
<td>109</td>
<td style="text-align: right;">39</td>
</tr>
</tbody>
</table>
</p>
<h3>About Airbnb</h3>
<p>Started in 2008, Airbnb is the world's largest online alternative accommodation travel agency, also offering booking services for boutique hotels and experiences. Airbnb's platform offered over 8 million active accommodation listings as of June 30, 2024. Listings from the company's over 5 million hosts are spread over almost every country in the world. In 2023, 50% of revenue was from the North American region. Transaction fees for online bookings account for all its revenue.</p>
<p>Having examined the options trading patterns of Airbnb, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Airbnb</h3>
<ul>
<li>With a volume of 1,412,660, the price of ABNB is up 1.67% at $131.18. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Airbnb, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

ABNB

Check Out What Whales Are Doing With ABNB

<p>Financial giants have made a conspicuous bearish move on ARM Holdings. Our analysis of options history for ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) revealed 37 unusual trades.</p>
<p>Delving into the details, we found 43% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 20 were puts, with a value of $1,114,075, and 17 were calls, valued at $834,962.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $220.0 for ARM Holdings over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ARM Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ARM Holdings's whale trades within a strike price range from $100.0 to $220.0 in the last 30 days. </p>
<h3>ARM Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197288_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$15.25</td>
<td>$14.95</td>
<td>$15.25</td>
<td>$220.00</td>
<td>$152.5K</td>
<td>232</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$12.6</td>
<td>$12.5</td>
<td>$12.6</td>
<td>$130.00</td>
<td>$138.6K</td>
<td>3.0K</td>
<td style="text-align: right;">110</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$9.05</td>
<td>$8.75</td>
<td>$8.75</td>
<td>$120.00</td>
<td>$122.5K</td>
<td>3.3K</td>
<td style="text-align: right;">140</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.6</td>
<td>$5.45</td>
<td>$5.45</td>
<td>$120.00</td>
<td>$81.7K</td>
<td>2.8K</td>
<td style="text-align: right;">168</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$15.1</td>
<td>$14.8</td>
<td>$14.99</td>
<td>$135.00</td>
<td>$74.9K</td>
<td>1.4K</td>
<td style="text-align: right;">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About ARM Holdings</h3>
<p>Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.</p>
<p>Following our analysis of the options activities associated with ARM Holdings, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of ARM Holdings</h3>
<ul>
<li>With a trading volume of 2,796,038, the price of ARM is up by 1.29%, reaching $143.56.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 52 days from now.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ARM Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


ARM Holdings's Options: A Look at What the Big Money is Thinking

<p>Financial giants have made a conspicuous bullish move on Advanced Micro Devices. Our analysis of options history for Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) revealed 53 unusual trades.</p>
<p>Delving into the details, we found 54% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $828,786, and 42 were calls, valued at $3,879,949.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $95.0 to $310.0 for Advanced Micro Devices during the past quarter. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Advanced Micro Devices options trades today is 5806.6 with a total volume of 174,966.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Advanced Micro Devices's big money trades within a strike price range of $95.0 to $310.0 over the last 30 days.</p>
<h3>Advanced Micro Devices Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197283_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$32.0</td>
<td>$31.1</td>
<td>$32.0</td>
<td>$210.00</td>
<td>$1.3M</td>
<td>0</td>
<td>430</td>
</tr>
<tr>
<td>AMD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/27/24</td>
<td>$2.99</td>
<td>$2.98</td>
<td>$2.99</td>
<td>$160.00</td>
<td>$287.6K</td>
<td>5.2K</td>
<td>4.9K</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$24.95</td>
<td>$24.9</td>
<td>$24.9</td>
<td>$165.00</td>
<td>$249.0K</td>
<td>2.2K</td>
<td>101</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$21.0</td>
<td>$20.95</td>
<td>$20.95</td>
<td>$160.00</td>
<td>$157.1K</td>
<td>4.6K</td>
<td>175</td>
</tr>
<tr>
<td>AMD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$9.5</td>
<td>$9.4</td>
<td>$9.45</td>
<td>$175.00</td>
<td>$130.4K</td>
<td>4.7K</td>
<td>212</td>
</tr>
</tbody>
</table>
</p>
<h3>About Advanced Micro Devices</h3>
<p>Advanced Micro Devices designs a variety of digital semiconductors for markets such as PCs, gaming consoles, data centers, industrial, and automotive applications, among others. AMD's traditional strength was in central processing units, CPUs, and graphics processing units, or GPUs, used in PCs and data centers. Additionally, the firm supplies the chips found in prominent game consoles such as the Sony PlayStation and Microsoft Xbox. In 2022, the firm acquired field-programmable gate array, or FPGA, leader Xilinx to diversify its business and augment its opportunities in key end markets such as the data center and automotive.</p>
<h3>Present Market Standing of Advanced Micro Devices</h3>
<ul>
<li>Trading volume stands at 16,008,069, with AMD's price up by 1.44%, positioned at $159.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Advanced Micro Devices, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Spotlight on Advanced Micro Devices: Analyzing the Surge in Options Activity

<p>7 analysts have expressed a variety of opinions on Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Zevra Therapeutics, revealing an average target of $19.71, a high estimate of $25.00, and a low estimate of $15.00. This current average reflects an increase of 8.48% from the previous average price target of $18.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197271_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Zevra Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Butler</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jonathan Aschoff</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zevra Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Zevra Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Zevra Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zevra Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ZVRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Zevra Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Zevra Therapeutics</h2>
<p>Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.</p>
<h3>Zevra Therapeutics: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Challenges:</strong> Zevra Therapeutics's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-47.47%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Zevra Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-447.85%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Zevra Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-49.02%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Zevra Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-13.48%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.83</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ZVRA

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock

<p>6 analysts have shared their evaluations of Mosaic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Mosaic, presenting an average target of $29.67, a high estimate of $32.00, and a low estimate of $27.00. This current average represents a 8.23% decrease from the previous average price target of $32.33. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197264_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Mosaic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Andrew Wong</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Andrew Wong</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Mosaic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Mosaic compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Mosaic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Mosaic's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MOS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Mosaic analyst ratings.</strong></a></p>
<h2>All You Need to Know About Mosaic</h2>
<p>Formed in 2004 by the combination of IMC Global and Cargill's fertilizer business, Mosaic is one of the largest phosphate and potash producers in the world. The company's assets include phosphate rock mines in Florida, Brazil, and Peru and potash mines in Saskatchewan, New Mexico, and Brazil. Mosaic also runs a large fertilizer distribution operation in Brazil through its Mosaic Fertilizantes business, which the company acquired from Vale in 2018.</p>
<h3>Key Indicators: Mosaic's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Mosaic's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately <strong>-17.01%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-5.73%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.36%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Mosaic's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.71%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Mosaic's debt-to-equity ratio is below the industry average. With a ratio of <b>0.38</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Mosaic

<p>Ratings for CF Industries Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CF#NYSE">CF</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for CF Industries Holdings, revealing an average target of $86.58, a high estimate of $100.00, and a low estimate of $78.00. This upward trend is evident, with the current average reflecting a 2.86% increase from the previous average price target of $84.17.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197236_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The standing of CF Industries Holdings among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Ben Isaacson</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$88.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Wong</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Joel Jackson</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Andrew Wong</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$78.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CF Industries Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CF Industries Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of CF Industries Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CF Industries Holdings analyst ratings.</strong></a></p>
<h2>About CF Industries Holdings</h2>
<p>CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making CF one of the lowest-cost nitrogen producers globally. The company is also investing in carbon-free blue and green ammonia, which can be used an alternative fuel to hydrogen or as a means to transport hydrogen.</p>
<h3>Financial Milestones: CF Industries Holdings's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Negative Revenue Trend:</strong> Examining CF Industries Holdings's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-11.44%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> CF Industries Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>26.72%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CF Industries Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.71%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> CF Industries Holdings's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.04%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> CF Industries Holdings's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.59</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into CF Industries Holdings Stock: Analyst Perspectives (12 Ratings)

<p>Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) has outperformed the market over the past 10 years by 7.27% on an annualized basis producing an average annual return of 18.5%. Currently, Primerica has a market capitalization of $8.96 billion. </p>
<p><strong>Buying $1000 In PRI:</strong> If an investor had bought $1000 of PRI stock 10 years ago, it would be worth <strong>$5,399.18</strong> today based on a price of $264.77 for PRI at the time of writing.</p>
<h3>Primerica's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197225_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Primerica Stock In The Last 10 Years

WIIM

EHang shares are trading higher after the company announced it achieved a major milestone with the completion of its first EH216-S pilotless eVTOL flight in Brazil.

<p>RBC Capital  analyst Brian Abrahams   maintains Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Outperform and lowers the price target from $1282 to $1252.</p>


REGN

RBC Capital Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $1252

<p>Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) has outperformed the market over the past 20 years by 10.25% on an annualized basis producing an average annual return of 18.66%. Currently, Synopsys has a market capitalization of $77.89 billion. </p>
<p><strong>Buying $1000 In SNPS:</strong> If an investor had bought $1000 of SNPS stock 20 years ago, it would be worth <strong>$32,172.59</strong> today based on a price of $507.04 for SNPS at the time of writing.</p>
<h3>Synopsys's Performance Over Last 20 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197220_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SNPS

Here's How Much You Would Have Made Owning Synopsys Stock In The Last 20 Years

<p>Analysts' ratings for Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Flowserve, presenting an average target of $58.14, a high estimate of $60.00, and a low estimate of $52.00. This upward trend is apparent, with the current average reflecting a 3.82% increase from the previous average price target of $56.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727197217_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A clear picture of Flowserve's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joseph Giordano</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Andrew Obin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Flowserve. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Flowserve compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Flowserve's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Flowserve's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Flowserve analyst ratings.</strong></a></p>
<h2>Delving into Flowserve's Background</h2>
<p>Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. In addition, Flowserve has a network of Quick Response Centers to provide aftermarket equipment services. The aftermarket services help customers with installation, diagnostics, repair, and retrofitting. Sales are roughly split across many regions, with North America and Europe contributing the majority of total revenue.</p>
<h3>Flowserve's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Flowserve's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>7.08%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>6.28%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Flowserve's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>3.7%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Flowserve's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.41%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.74</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Flowserve

CSCO

iShares Trust Dow Jones US Real Estate Fund Index

PYPL

CNBC Halftime Report Final Trades: PayPal Holdings, Cisco Systems, Citizens Financial Group, iShares U.S. Real Estate ETF

Macro Notification

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

Israel's UN Envoy Says Israel Is Open To U.S. Ideas For De-Escalation In Lebanon And Prefers Diplomatic Solutions Over Ground Invasions

<p><strong>Diamondback Energy, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), <strong>Kinetik Holdings Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNTK#NYSE">KNTK</a>), and EPIC Midstream Holdings disclosed a series of transactions to enhance the growth and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40998581/diamondback-energy-kinetik-holdings-and-epic-midstream-announce-transformative-transactions-for-ep" rel="noreferrer noopener">financial profile of EPIC Crude Holdings, LP</a>.</p>
<p>As part of the deal, Diamondback and Kinetik acquired a 30% equity interest in EPIC Crude, with each now owning 27.5% of the company.</p>
<p>EPIC Midstream holds a 45% equity interest in EPIC Crude and manages its operations.</p>
<p>EPIC Crude transports over 600 MBpd and has secured MVCs for about 90% of its 2025 volumes, extending the weighted average contract life. Its strategy allows customers access to all markets and docks in Corpus Christi, as well as the Dated Brent market, through the EPIC dock.</p>
<p>Diamondback is increasing its commitment to 200 MBpd to accommodate additional crude from its merger with Endeavor Energy Resources, positioning it as the third-largest crude producer in the Permian Basin.</p>
<p>On the other hand, Kinetik is establishing a new transportation arrangement with EPIC Crude, linking its crude gathering system to the EPIC Crude pipeline.</p>
<p>The combined long-term volume commitments from both partners will begin in 2025 and extend to 2035, representing over 33% of EPIC Crude&#8217;s capacity.</p>
<p>These efforts aim to reduce costs and enhance financial returns, ensuring long-term success and strategic alignment among the partners.</p>
<p>Kaes&nbsp;Van&#8217;t&nbsp;Hof,&nbsp;President&nbsp;and Chief&nbsp;Financial&nbsp;Officer&nbsp;of Diamondback, said, &#8220;This series of transactions signifies a&nbsp;major step in ensuring&nbsp;reliable,&nbsp;cost-effective&nbsp;takeaway out of&nbsp;the basin&nbsp;for our expanded crude portfolio&nbsp;for a significant period of time, and&nbsp;positions EPIC&nbsp;Crude to be our preferred crude pipeline given our increased ownership stake and expanded governance role in the joint venture.&#8221;</p>
<p>Jamie Welch, President and Chief Executive Officer of Kinetik, stated, &#8220;Our volume commitment, alongside Diamondback, will generate incremental value for our crude customers seeking access to a premium market.&#8221;</p>
<p><strong>Price Action</strong>: FANG shares are up 0.18% at $185.58, and KNTK is down 0.18% at $47.20 at the last check Tuesday.</p>
<p><em>Image via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/large-cap/24/08/40313301/oil-prices-eye-fourth-straight-day-of-gains-as-geopolitical-risks-overshadow-opecs-cooler-demand-f" target="_blank" rel="noreferrer noopener">Oil Prices Eye Fourth Straight Day Of Gains As Geopolitical Risks Overshadow OPEC&#8217;s Cooler Demand Forecast</a></strong></li>
</ul>


Equities

Large Cap

KNTK

Diamondback Energy, Kinetik Strengthen Stake In EPIC Crude With New Deal And Long-Term Commitments

<p><strong>AngloGold Ashanti</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/au#NYSE">AU</a>) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.</p>
<p>The sole determinant of the Zacks rating is a company&#39;s changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.</p>
<p>Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.</p>
<p>As such, the Zacks rating upgrade for AngloGold Ashanti is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.</p>
<h2>Most Powerful Force Impacting Stock Prices</h2>
<p>The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That&#39;s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.</p>
<p>For AngloGold Ashanti, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.</p>
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
<p>As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.</p>
<p>The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.</p>
<h2>Earnings Estimate Revisions for AngloGold Ashanti</h2>
<p>This gold miner is expected to earn $2.58 per share for the fiscal year ending December 2024, which represents a year-over-year change of 2445.5%.</p>
<p>Analysts have been steadily raising their estimates for AngloGold Ashanti. Over the past three months, the Zacks Consensus Estimate for the company has increased 9.1%.</p>
<h2>Bottom Line</h2>
<p>Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.</p>
<p>The upgrade of AngloGold Ashanti to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.</p>
<p><a href="https://www.zacks.com/stock/news/2340055/what-makes-anglogold-ashanti-au-a-new-strong-buy-stock?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340055">To read this article on Zacks.com click here.</a></p>


Earnings

Upgrades

What Makes AngloGold Ashanti a New Strong Buy Stock

HUMA

Humacyte Option Alert: Oct 18 $7.5 Calls Sweep (30) Near The Ask: 1246 @ $0.201 Vs 4796 OI; Earnings 11/7 After Close [est] Ref=$5.72

<p>Momentum investing revolves around the idea of following a stock&#39;s recent trend in either direction. In the &#39;long&#39; context, investors will be essentially be &quot;buying high, but hoping to sell even higher.&quot; With this methodology, taking advantage of trends in a stock&#39;s price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.</p>
<p>Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score helps address this issue for us.</p>
<p>Below, we take a look at <strong>Packaging Corp.</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pkg#NYSE">PKG</a>), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.</p>
<p>It&#39;s also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Packaging Corp. Currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.</p>
<h2>Set to Beat the Market?</h2>
<p>In order to see if PKG is a promising momentum pick, let&#39;s examine some Momentum Style elements to see if this maker of containerboard and corrugated packaging products holds up.</p>
<p>Looking at a stock&#39;s short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It&#39;s also helpful to compare a security to its industry; this can show investors the best companies in a particular area.</p>
<p>For PKG, shares are up 1.25% over the past week while the Zacks Containers - Paper and Packaging industry is up 2.38% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 4.46% compares favorably with the industry&#39;s 1.77% performance as well.</p>
<p>While any stock can see its price increase, it takes a real winner to consistently beat the market. That is why looking at longer term price metrics -- such as performance over the past three months or year -- can be useful as well. Shares of Packaging Corp. Have increased 16.62% over the past quarter, and have gained 42.83% in the last year. On the other hand, the S&amp;P 500 has only moved 4.57% and 31.09%, respectively.</p>
<p>Investors should also pay attention to PKG&#39;s average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. PKG is currently averaging 512,829 shares for the last 20 days.</p>
<h2>Earnings Outlook</h2>
<p>The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock&#39;s price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with PKG.</p>
<p>Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost PKG&#39;s consensus estimate, increasing from $8.50 to $8.72 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been no downward revisions in the same time period.</p>
<h2>Bottom Line</h2>
<p>Taking into account all of these elements, it should come as no surprise that PKG is a #2 (Buy) stock with a Momentum Score of B. If you&#39;ve been searching for a fresh pick that&#39;s set to rise in the near-term, make sure to keep Packaging Corp. On your short list.</p>
<p><a href="https://www.zacks.com/stock/news/2340049/are-you-looking-for-a-top-momentum-pick-why-packaging-corp-pkg-is-a-great-choice?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_10-2340049">To read this article on Zacks.com click here.</a></p>


Short Ideas

Are You Looking for a Top Momentum Pick? Why Packaging Corp. is a Great Choice

<p><strong>Novo Nordisk A/S</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) will consider ways to help patients <a href="https://www.benzinga.com/general/biotech/24/09/40997408/miracle-weight-loss-drug-ozempic-to-enter-us-price-negotiations-within-a-year-novo-nordisk-ceo-sa">get affordable prescriptions</a> for weight loss drugs, CEO <strong>Lars Fruergaard Jorgensen </strong>told members of the U.S. Congress on Wednesday when asked if his company would lower U.S. prices for Ozempic and Wegovy.</p>
<p>Jorgensen sat before the Health, Education, Labor and Pensions Committee, led by Sen. <strong>Bernie Sanders </strong>(I-Vt.), to answer questions on why Ozempic costs $969 per month in the U.S. versus only $155 per month in Canada, $122 in Denmark, $59 in Germany and $71 in France.</p>
<p>A month&#8217;s prescription for Wegovy in the U.S. costs $1,349, compared to $186 in Denmark, $140 in Germany and $92 in the U.K.</p>
<p>&#8220;You&#8217;re making huge amounts of money in this country and you&#8217;re charging us far more and you haven&#8217;t given me an answer as to why,&#8221; Sanders said to Jorgensen during the hearing.</p>
<p>Sanders then told Jorgensen that pharmacy benefit managers (PBM) would keep both Ozempic and Wegovy on their insurance coverage lists if his company substantially lowered the prices of these drugs in the U.S.</p>
<p>&#8220;I have received commitments in writing from the major PBMs that if Novo Nordisk lowered its list price, they would not limit access to Ozempic and Wegovy and would not take these drugs off of their formularies,&#8221; Sanders said.</p>
<p><strong>Read Also:</strong> <strong><a href="https://www.benzinga.com/general/biotech/23/08/34041655/wegovys-massive-demand-novo-nordisk-ceo-expresses-full-confidence-in-catalent-amid-manufacturing-">Wegovy&#8217;s Massive Demand: Novo Nordisk CEO Expresses Full Confidence In Catalent Amid Manufacturing Hurdles</a></strong></p>
<p>&#8220;Given this fact, will you commit today that Novo Nordisk will substantially reduce the list price of these drugs in the United States so that the American people are not paying higher prices, far higher prices for these drugs than the people in Europe and Canada?&#8221;</p>
<p>Jorgensen said his company will examine ways to give U.S. patients &#8220;access to affordable medicine&#8221; after hearing of this commitment for the first time.</p>
<p>&#8220;Thank you, senator, for for that information. That&#8217;s new information for me,&#8221; he said.</p>
<p>&#8220;Anything that will help patients get access to affordable medicine, we&#8217;ll be happy to look into.&#8221;</p>
<p>But he said he was a bit concerned by the commitment because an insulin medicine made by Novo Nordisk was dropped from PBM&#8217;s formularies after the company dropped internet pricing for the drug last year.</p>
<p>&#8220;I have a bit of concern how this could play out but anything that can help patients get access to the medicines they need at affordable price point will be happy to collaborate around that,&#8221; Jorgensen said. </p>
<p>Sanders asked Jorgensen if he would be willing to sit down with governors to work on an agreement to lower the prices for Ozempic and Wegovy, based on the commitment from PBMs.</p>
<p>&#8220;I&#8217;d be happy to, as I said to anything that helps patients,&#8221; he said. &#8220;I don&#8217;t know under which conditions such a promise comes. I haven&#8217;t seen any of that.&#8221;</p>
<p><strong>NVO Price Action: </strong>Novo Nordisk rose 2.25% to $126.48 into Tuesday&#8217;s mid-day trading.</p>
<p><strong>Read Now:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/23/10/35449786/weight-loss-drugs-wegovy-ozempic-gain-traction-with-millennials-high-earners-new-survey-results">Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results</a></strong></li>
</ul>
<p><em>Photo: Natalia Varlei On Shutterstock</em></p>


Biotech

Government

Health Care

Global

Insurance

Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO

RosCan Gold Corporation (TSE:ROS) has released an update. Roscan Gold Corporation, a Canadian-based mining company, has announced an increase in it...

Roscan Gold Upsizes Financing Amid High Demand

Roscan Gold announces upsize to proposed financing

RosCan Gold Corporation (TSE:ROS) has released an update. Roscan Gold Corporation has successfully completed the first tranche of its non-brokered ...

Roscan Gold Secures Funding Through Private Placement

RosCan Gold Corporation (TSE:ROS) has released an update. Roscan Gold Corporation has concluded a debt settlement agreement involving a $1,050,000 ...

Roscan Gold Settles Debt with Equity and Note

RosCan Gold (TSE:ROS) has released an update. Roscan Gold Corporation recently held its Annual General Meeting, where shareholders overwhelmingly s...

Roscan Gold Shareholders Approve Key Resolutions

RosCan Gold (TSE:ROS) has released an update. Roscan Gold Corporation is set to extend the maturity date of its $1,000,000 promissory notes by one ...

Roscan Gold Extends Promissory Note Maturity

Roscan Gold gets extension to promissory notes and private placement

RosCan Gold (TSE:ROS) has released an update. Roscan Gold Corporation has extended the maturity date of its $1,000,000 promissory notes to Septembe...

Roscan Gold Strengthens Capital with New Financial Moves

RosCan Gold (TSE:ROS) has released an update. Roscan Gold Corporation announces significant changes to its Board of Directors, with Mr. Nana Sangmu...

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Roscan Gold

News

Latest news for Roscan Gold (OTC:RCGCF) Stock

Monday, November 11, 2019